Astrazeneca PLC (AZN) : Traders are bullish on Astrazeneca PLC (AZN) as it has outperformed the S&P 500 by a wide margin of 2.86% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.47%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.03% in the last 1 week, and is up 0.77% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 1.86% and the 50-Day Moving Average is 4.31%.The 200 Day SMA reached 12.11% AstraZeneca PLC is up 24.26% in the last 3-month period. Year-to-Date the stock performance stands at 4.21%.
Astrazeneca PLC (AZN) : The highest short term price target forecast on Astrazeneca PLC (AZN) is $41 and the lowest target price is $34. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $36.79 with a standard deviation of $4.
For the current week, the company shares have a recommendation consensus of Buy. Astrazeneca PLC (NYSE:AZN): The stock opened at $34.12 and touched an intraday high of $34.15 on Friday. During the day, the stock corrected to an intraday low of $33.68, however, the bulls stepped in and pushed the price higher to close in the green at $33.82 with a gain of 0.48% for the day. The total traded volume for the day was 5,154,736. The stock had closed at $33.82 in the previous trading session.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).